Kronos Bio, Inc. (KRON)
- Previous Close
0.8990 - Open
0.9000 - Bid 0.8800 x 2100
- Ask 1.1700 x 200
- Day's Range
0.8925 - 0.9299 - 52 Week Range
0.6900 - 1.6000 - Volume
95,534 - Avg. Volume
151,934 - Market Cap (intraday)
54.433M - Beta (5Y Monthly) 1.79
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4300 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren's disease. The company was incorporated in 2017 and is headquartered in San Mateo, California.
www.kronosbio.comRecent News: KRON
View More
Performance Overview: KRON
Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KRON
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KRON
View MoreValuation Measures
Market Cap
54.62M
Enterprise Value
-32.91M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.46
Price/Book (mrq)
0.62
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.48%
Return on Equity (ttm)
-69.80%
Revenue (ttm)
9.85M
Net Income Avi to Common (ttm)
-86.08M
Diluted EPS (ttm)
-1.4300
Balance Sheet and Cash Flow
Total Cash (mrq)
112.42M
Total Debt/Equity (mrq)
28.43%
Levered Free Cash Flow (ttm)
-30.74M